Similar trend was observed for BR1 expression on CD14++CD16− that also revealed a significant difference between HAE patients during the attack (30.63%; 18.99–64.21%) and the remission state (21.83%; 9.15–33.43%; p = 0.00015) and healthy subjects (19.80%; 10.97–69.38%; p = 0.00012; Figure 3/Table 2). The gene discussed is CXCL11; the disease is hereditary angioedema.